Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance

Cristina Jiménez-Ortigosa, Winder B. Perez, David Angulo, Katyna Borroto-Esoda, David S. Perlin
Cristina Jiménez-Ortigosa
aPublic Health Research Institute, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Newark, New Jersey, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Winder B. Perez
aPublic Health Research Institute, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Newark, New Jersey, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Angulo
bScynexis, Inc., Jersey City, New Jersey, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katyna Borroto-Esoda
bScynexis, Inc., Jersey City, New Jersey, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David S. Perlin
aPublic Health Research Institute, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Newark, New Jersey, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.00833-17
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

SCY-078 is an orally active antifungal whose target is the β-(1,3)-d-glucan synthase (GS). We evaluated the spontaneous emergence of SCY-078-resistant Candida glabrata isolates following drug exposure in vitro. Resistant isolates were analyzed using broth microdilution methodology and FKS sequencing. The kinetic inhibition parameter IC50 (50% inhibitory concentration) was also determined from GS complexes. The spectrum of resistance mutations found suggested a partially overlapping but independent binding site for SCY-078 relative to echinocandins on GS.

TEXT

The echinocandins are preferred first-line agents for treating severe invasive fungal infections due to Candida species (1). They alter the integrity of the fungal cell wall via inhibition of the biosynthesis of its major component, β-(1,3)-glucan (2). The echinocandins target the catalytic subunit of the enzymatic complex β-(1,3)-d-glucan synthase, which is encoded by the FKS genes. The three FDA-approved echinocandins (caspofungin, anidulafungin, and micafungin) are only available as intravenous formulations, which limits their application, especially as oral step-down agents as often required outside the hospital setting. SCY-078 (formerly MK-3118) is an orally active semisynthetic derivative of the natural product enfumafungin, which is a potent inhibitor of fungal β-(1,3)-d-glucan synthases (3) with a chemical structure that is distinct from that of the echinocandins (Fig. 1). SCY-078 is highly active against clinically important Candida species, including some variants that are resistant to echinocandin drugs (4) (5). There is some cross-resistance between echinocandin-resistant strains and SCY-078, but little is known about the spectrum of de novo reduced susceptibility induced by this new chemical class of antifungal agent. The goal of this study was to understand the nature of de novo reduced susceptibility following in vitro selection with SCY-078 against the important human pathogen Candida glabrata, as it is the predominant Candida species responsible for antifungal drug resistance (azole and echinocandin) observed in the United States and Europe (6).

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Structures of SCY-078, a semisynthetic enfumafungin derivative, and micafungin, an echinocandin.

In order to obtain spontaneous isolates with reduced susceptibility to SCY-078, C. glabrata cells (1 × 106) from different susceptible clinical isolates (Table 1) were plated on SCY-078-containing yeast extract-peptone-dextrose (YPD) plates (1% yeast extract, 2% peptone, 2% glucose) on a range of 1 dilution above to 1 dilution below the MIC (0.25 to 1 μg/ml). SCY-078-resistant (SR) isolates were selected following incubation at 37°C for 5 days, as modified from Balashov (7). The susceptible strains were obtained from epidemiologically distinct patients with bloodstream infection (BSI). Two strains, BAD55 and BAD144, showed a point mutation in the mismatch repair gene MSH2 (P208S) that has been linked to a higher propensity to breakthrough antifungal treatment in vitro (8). Breakthrough colonies were detected only on media plates containing 0.5× the MIC (0.25 μg/ml) of the antifungal drug for all strains except BAD55. After the initial selection, a total of 104 isolates (40 for BAD40, 48 for BAD144, and 16 for BAD47) were screened for growth on YPD plates containing increasing concentrations of SCY-078 (0.5 to 4 μg/ml). Of the 104 isolates, 17 failed to grow when subcultured on YPD plates with 4 μg/ml of SCY-078 and were not further analyzed. Antifungal susceptibility testing was performed in triplicate for the remaining 87 isolates in accordance with the guidelines described in CLSI document M27-A3 (9) for SCY-078 and the comparator agent micafungin (MCF). MCF (Astellas Pharma, Inc.) and SCY-078 (Scynexis, Inc.) were obtained as standard powders from their manufacturers and dissolved in water (MCF) or 100% dimethyl sulfoxide (DMSO) (SCY-078). Geometric MIC distributions ranged from 0.31 to 8 and 0.03 to 2.52 μg/ml for SCY-078 and MCF, respectively (Table 2).

View this table:
  • View inline
  • View popup
TABLE 1

Antifungal susceptibility of the strains used in this studya

View this table:
  • View inline
  • View popup
TABLE 2

MIC distributions of SCY-078 and MCF for the SCY-078-resistant C. glabrata isolates

Reduced echinocandin susceptibility leading to therapeutic failure has been linked to mutations in two highly conserved hot spot regions (HS1 and HS2) in the catalytic FKS subunit of β-(1,3)-d-glucan synthase (10, 11). Since SCY-078 also targets β-(1,3)-d-glucan synthase, we determined the spectrum of possible mutations in the SR C. glabrata isolates by sequencing both FKS1 and FKS2 genes. A total of 15 SR isolates harbored mutations in either the FKS1 (n = 2) or FKS2 (n = 13) genes, leading to an amino acid change (Table 2). The majority of mutations were localized to amino acid (aa) Phe659 within the HS1 region of FKS2 (aa 659 to 667). In the clinical setting, fks mutations affecting Fks1 Ser629, Fks2 Ser663, and Phe659 in C. glabrata are some of the most commonly observed mutations. These mutations confer some of the largest MIC (and glucan synthase 50% inhibitory concentration [IC50]) shifts (10, 12); in the present in vitro study, only one echinocandin-resistant locus, Phe659, was identified. Interestingly, three resistant isolates displayed mutations in other regions of FKS2. One isolate contained a mutation upstream of HS1 (BAD40-18 [Glu655Ala]), while another had a mutation downstream of HS2 (aa 1374 to 1381) (BAD40-18 [Ala1390Asp]). Isolate BAD40-36 contained a Trp715Leu mutation, for which the equivalent has been shown to alter echinocandin susceptibility in Saccharomycescerevisiae (13). Isolates bearing FKS mutations exhibited higher MIC values for SCY-078 and MCF relative to their parent strain (Table 2), with fold decreases in susceptibility ranging from 1.58 to 16 and 2 to 84 for SCY-078 and MCF, respectively. Notably, one isolate displayed an elevated MIC for MCF but lacked a mutation in either FKS1 or FKS2 (BAD144-6; MIC, ≥0.25 μg/ml).

To better assess direct inhibition of SCY-078 on glucan synthase, the kinetic inhibition parameter IC50 (half maximal inhibitory concentration) was determined for glucan synthases from wild-type and SCY-078-resistant fks-containing strains. Product-entrapped β-(1,3)-d-glucan synthase complexes were extracted as described previously (10). The inhibition curves for MCF and SCY-078 against the wild-type (WT) C. glabrata isolates showed the typical pattern of β-(1,3)-d-glucan synthase echinocandin susceptibility reported for other sensitive Candida species (12) with mean IC50s of 1.64 to 5.18 ng/ml for MCF and 13.97 to 82.15 ng/ml for SCY-078 (Table 3).

View this table:
  • View inline
  • View popup
TABLE 3

IC50s of β-(1,3)-d-glucan synthases from susceptible and SCY-078-resistant C. glabrata isolates

Evaluation of kinetic inhibition of the product-entrapped enzymes isolated from SR strains yielded higher IC50s for SCY-078 and MCF than enzymes from the corresponding parent strains. The Fks2 Phe659del mutant was strongly insensitive to all drugs and exhibited 44- and >121-fold increases in IC50 for MCF and SCY-078, respectively. The Fks1 Phe625del mutant was also highly insensitive, with 11- and 40-fold increases for MCF and SCY-078, respectively (Fig. 2 and Table 3). In contrast, a point mutation (Phe625Leu) at this same locus had little effect on MIC, and the isolated enzyme displayed strong sensitivity to the assayed drugs. Regarding the novel mutations found outside the hot spot (HS) in the FKS2 gene, GS enzymes containing either Ala1390Asp or Trp715Leu proved to be highly insensitive to SCY-078 (20- and 29-fold increases in IC50, respectively) (Table 3). This correlates well with the high MICs these mutants showed for SCY-078 (4 μg/ml for Trp715Leu and 8 μg/ml for Ala1390Asp) but not for MCF (0.3 μg/ml for Trp715Leu and 0.12 μg/ml for Ala1390Asp). The fact that different mutations in the FKS genes had such diverse IC50 profiles suggests that even though SCY-078 and the echinocandins inhibit the same target enzyme, the interaction sites between these two types of antifungal drugs overlap but are not identical.

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

Antifungal inhibition profiles of enriched GS complexes from representative susceptible and SCY-078-resistant C. glabrata isolates for micafungin (MCF) and SCY-078.

We observed a similar pattern in IC50s in previous work (5); mutations in Ser645 in Candida albicans within hot spot 1 in the FKS1 gene resulted in an increase in susceptibility to SCY-078 compared to caspofungin (5.5-fold change), but mutations in Phe641 proved to be extremely resistant to both antifungal drugs. In C. glabrata, substitutions at the Phe659 locus within hot spot 1 in the FKS2 gene (equivalent to Phe641 in C. albicans) showed an increase in the susceptibility to SCY-078 compared to that to CSF (3.6-fold change). This behavior is also consistent with the MIC data (5).

In summary, C. glabrata isolates harboring FKS mutations show reduced susceptibility to SCY-078 (1.58-to 16-fold increase in MIC values for SCY-078). The isolated enzymes harboring mutations in or outside the echinocandin-resistant HS regions were more sensitive to MCF, with an IC50 between 3- to 43-fold lower than those for SCY-078. Of the 15 SCY-078-resistant isolates generated from the screen showing FKS mutations, 13 of them contained a mutation in FKS2, correlating with previous findings that glucan synthase expression may be predominantly derived from FKS2 in C. glabrata (11). The absence of mutations found at prominent echinocandin resistance hot spot loci Ser663 (FKS2) and Ser629 (FKS1) is consistent with in vitro studies showing that SCY-078 is active against echinocandin-resistant strains with mutations at these positions (4, 5). This would suggest that FKS2 may be under greater selective pressure relative to FKS1, and the identification of resistant mutations inside and outside FKS hot spot regions indicates a partially shared interaction site among SCY-078 and the echinocandins (Fig. 3). This is also supported by previous in vitro selection studies involving both caspofungin and micafungin in which other prominent loci associated with echinocandin resistance were identified (13).

FIG 3
  • Open in new tab
  • Download powerpoint
FIG 3

Prediction model of C. glabrata Fks2 membrane protein topology (gray bars, transmembrane regions [TMH]; hot spot regions are marked with green circles). Note that amino acids in positions 715 and 1390 (marked with blue dots) are in TMHVI and TMHVIII, respectively. In silico TMH predictions were generated using TMHMM (http://www.cbs.dtu.dk/services/TMHMM ) and PRO-TMHMM (http://topcons.cbr.su.se ).

In conclusion, the molecular target on glucan synthase conferring resistance to SCY-078 displays partial overlap with that for echinocandin drugs, but the binding site appears to be nonidentical.

ACKNOWLEDGMENTS

This work was supported by a grant from Scynexis, Inc., and NIH grant R01AI109025 to D.S.P.

FOOTNOTES

    • Received 27 April 2017.
    • Returned for modification 19 May 2017.
    • Accepted 5 June 2017.
    • Accepted manuscript posted online 19 June 2017.
  • Copyright © 2017 American Society for Microbiology.

All Rights Reserved .

REFERENCES

  1. 1.↵
    1. Pappas PG,
    2. Kauffman CA,
    3. Andes D,
    4. Benjamin DK Jr.,
    5. Calandra TF,
    6. Edwards JE Jr.,
    7. Filler SG,
    8. Fisher JF,
    9. Kullberg BJ,
    10. Ostrosky-Zeichner L,
    11. Reboli AC,
    12. Rex JH,
    13. Walsh TJ,
    14. Sobel JD,
    15. Infectious Diseases Society of America
    . 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis48:503–535. doi:10.1086/596757.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Denning DW
    . 2003. Echinocandin antifungal drugs. Lancet362:1142–1151. doi:10.1016/S0140-6736(03)14472-8.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Onishi J,
    2. Meinz M,
    3. Thompson J,
    4. Curotto J,
    5. Dreikorn S,
    6. Rosenbach M,
    7. Douglas C,
    8. Abruzzo G,
    9. Flattery A,
    10. Kong L,
    11. Cabello A,
    12. Vicente F,
    13. Pelaez F,
    14. Diez MT,
    15. Martin I,
    16. Bills G,
    17. Giacobbe R,
    18. Dombrowski A,
    19. Schwartz R,
    20. Morris S,
    21. Harris G,
    22. Tsipouras A,
    23. Wilson K,
    24. Kurtz MB
    . 2000. Discovery of novel antifungal (1,3)-beta-d-glucan synthase inhibitors. Antimicrob Agents Chemother44:368–377. doi:10.1128/AAC.44.2.368-377.2000.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Pfaller MA,
    2. Messer SA,
    3. Motyl MR,
    4. Jones RN,
    5. Castanheira M
    . 2013. Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST). J Antimicrob Chemother68:858–863. doi:10.1093/jac/dks466.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Jimenez-Ortigosa C,
    2. Paderu P,
    3. Motyl MR,
    4. Perlin DS
    . 2014. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates. Antimicrob Agents Chemother58:1248–1251. doi:10.1128/AAC.02145-13.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Guinea J
    . 2014. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect20(Suppl 6):S5–S10. doi:10.1111/1469-0691.12539.
    OpenUrlCrossRef
  7. 7.↵
    1. Balashov SV,
    2. Park S,
    3. Perlin DS
    . 2006. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother50(6):2058–2063. doi:10.1128/AAC.01653-05.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Healey KR,
    2. Zhao Y,
    3. Perez WB,
    4. Lockhart SR,
    5. Sobel JD,
    6. Farmakiotis D,
    7. Kontoyiannis DP,
    8. Sanglard D,
    9. Taj-Aldeen SJ,
    10. Alexander BD,
    11. Jimenez-Ortigosa C,
    12. Shor E,
    13. Perlin DS
    . 2016. Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance. Nat Commun7:11128. doi:10.1038/ncomms11128.
    OpenUrlCrossRefPubMed
  9. 9.↵
    Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. CLSI document M27-A3,3rd ed,Vol. 28. Clinical and Laboratory Standards Institute,Wayne, PA.
  10. 10.↵
    1. Garcia-Effron G,
    2. Lee S,
    3. Park S,
    4. Cleary JD,
    5. Perlin DS
    . 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-d-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother53:3690–3699. doi:10.1128/AAC.00443-09.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Perlin DS
    . 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat10:121–130. doi:10.1016/j.drup.2007.04.002.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Garcia-Effron G,
    2. Park S,
    3. Perlin DS
    . 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother53:112–122. doi:10.1128/AAC.01162-08.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Johnson ME,
    2. Katiyar SK,
    3. Edlind TD
    . 2011. New Fks hot spot for acquired echinocandin resistance in Saccharomyces cerevisiae and its contribution to intrinsic resistance of Scedosporium species. Antimicrob Agents Chemother55:3774–3781. doi:10.1128/AAC.01811-10.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance
Cristina Jiménez-Ortigosa, Winder B. Perez, David Angulo, Katyna Borroto-Esoda, David S. Perlin
Antimicrobial Agents and Chemotherapy Aug 2017, 61 (9) e00833-17; DOI: 10.1128/AAC.00833-17

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance
Cristina Jiménez-Ortigosa, Winder B. Perez, David Angulo, Katyna Borroto-Esoda, David S. Perlin
Antimicrobial Agents and Chemotherapy Aug 2017, 61 (9) e00833-17; DOI: 10.1128/AAC.00833-17
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

antifungal agents
Candida glabrata
Drug Resistance, Fungal
echinocandins
Fungal Proteins
Glycosides
mutation
Triterpenes
Candida glabrata
SCY-078
resistance

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596